Psychiatric morbidity among men using anabolic steroids

Josefine Windfeld-Mathiasen*, Thea Christoffersen, Niels August Willer Strand, Kim Dalhoff, Jon Traerup Andersen, Henrik Horwitz

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

9 Citations (Scopus)
19 Downloads (Pure)

Abstract

Objective The purpose of this study was to investigate the psychiatric morbidity among men with abuse of anabolic steroids. Methods The design is a retrospectively matched cohort study. Five hundred and fourty-five males, who tested positive for anabolic steroids in Danish fitness centers during the period January 3, 2006 to March 1, 2018, were matched with 5450 randomly chosen male controls. Data was cross-referenced with seven national registers pertaining to information about education, employment status, and psychiatric comorbidity. Main outcomes and measures were prescription of psychopharmacological treatment. Results The incidence of treatment with anxiolytics (HR: 2.34, 95% CI: 1.62-3.38) and antipsychotics (HR: 2.69, 95% CI: 1.99-3.63) displayed a remarkable increase in the years following doping sanction, compared to the control group. The prevalence of antidepressant use was already markedly elevated several years before doping sanction, but also displayed a higher incidence in the years following sanction (HR: 1.65, 95% CI: 1.28-2.13). The associations remained highly significant after controlling for socioeconomic factors. Conclusion Anabolic steroids use is strongly associated with psychiatric morbidity.

Original languageEnglish
JournalDepression and Anxiety
Volume39
Issue number12
Pages (from-to)805-812
Number of pages8
ISSN1091-4269
DOIs
Publication statusPublished - 2022

Keywords

  • androgenic anabolic steroids
  • depression
  • depressive adverse reactions
  • neuropsychiatric effects
  • ANXIETY

Cite this